Table 1.
Four single-nucleotide polymorphisms (SNPs) associated with non-cardia gastric cancer risk above genome-wide significance level
| Cytoband (BP) | NCBI dbSNP identifier, build 138 (referent, effect allele) | Nearest gene | Group | Effect allele frequency (case, control) | OR (95% CI) | p Value | Phet | I2 |
|---|---|---|---|---|---|---|---|---|
| 1q22 | rs80142782 | ASH1L | NCI | 0.06, 0.07 | 0.68 (0.55 to 0.86) | 7.44E-04 | ||
| 155485027 | (T,C) | Beijing | 0.03, 0.07 | 0.47 (0.27 to 0.80) | 5.39E-03 | |||
| Nanjing | 0.04, 0.08 | 0.56 (0.38 to 0.82) | 2.55E-03 | |||||
| Stage 2a | 0.05, 0.09 | 0.61 (0.50 to 0.73) | 1.46E-07 | |||||
| Stage 2b | 0.05, 0.07 | 0.64 (0.54 to 0.75) | 1.16E-07 | |||||
| Combined | 0.62 (0.56 to 0.69) | 1.71E-19 | 0.66 | 0.00 | ||||
| 1q22 | rs4072037 | MUC1 | NCI | 0.14, 0.16 | 0.76 (0.65 to 0.87) | 1.31E-04 | ||
| 155162067 | (T,C) | Beijing | 0.10, 0.14 | 0.87 (0.61 to 1.22) | 4.17E-01 | |||
| Nanjing | 0.13, 0.16 | 0.84 (0.66 to 1.08) | 1.70E-01 | |||||
| Stage 2a | 0.13, 0.19 | 0.68 (0.59 to 0.77) | 9.63E-09 | |||||
| Stage 2b | 0.12, 0.16 | 0.75 (0.67 to 0.84) | 1.22E-06 | |||||
| Combined | 0.74 (0.69 to 0.79) | 6.28E-17 | 0.44 | 0.00 | ||||
| 5q14.3 | rs7712641 | NA | NCI | 0.44, 0.46 | 0.88 (0.79 to 0.97) | 1.14E-02 | ||
| 88902964 | (C,T) | Beijing | 0.41, 0.47 | 0.75 (0.60 to 0.93) | 9.41E-03 | |||
| Nanjing | 0.45, 0.48 | 0.79 (0.67 to 0.94) | 7.54E-03 | |||||
| Stage 2a | 0.43, 0.48 | 0.81 (0.73 to 0.90) | 4.91E-05 | |||||
| Stage 2b | 0.42, 0.46 | 0.86 (0.79 to 0.94) | 4.94E-04 | |||||
| Combined | 0.84 (0.80 to 0.88) | 1.21E-11 | 0.56 | 0.00 | ||||
| 8q24.3 | rs2294008 | PSCA | NCI | 0.31, 0.29 | 1.16 (1.03 to 1.31) | 1.18E-02 | ||
| 143761931 | (C,T) | Beijing | 0.39, 0.34 | 1.29 (1.01 to 1.64) | 4.30E-02 | |||
| Nanjing | 0.36, 0.32 | 1.22 (1.00 to 1.48) | 4.78E-02 | |||||
| Stage 2a | 0.29, 0.25 | 1.16 (1.04 to 1.30) | 9.04E-03 | |||||
| Stage 2b | 0.31, 0.26 | 1.26 (1.15 to 1.39) | 1.24E-06 | |||||
| Combined | 1.20 (1.15 to 1.28) | 5.95E-11 | 0.76 | 0.00 |
Bold indicates combined results using meta-analysis based method.
BP, base pair; C, cytosine; dbSNP, the Single Nucleotide Polymorphism database; NA, not available; NCI, National Cancer Institute; PSCA, prostate stem cell antigen; T, thymine.